drugset / Trial / NCT03835884
A Study Assessing AR-13503 Implant in Subjects With nAMD or DME
RandomizedSequentialOpen-labelTreatment
Summary
First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)
Timeline
- Start
- 2019-06-24
- Primary completion
- 2022-05-12
- Completion
- 2022-05-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AR-13503 | Unknown | 10.6 ug | Intravitreal |
| Subject | AR-13503 | Unknown | 21.2 ug | Intravitreal |
| Subject | AR-13503 | Unknown | 42.4 ug | Intravitreal |
| Subject | AR-13503 | Unknown | 63.6 ug | Intravitreal |